Doctor’s Passport

Find your next topic

Explore the current textbook

Available drafts · Clinical review pending
Membership
Educational draft · awaiting clinical reviewThe full textbook explains uncertainty but does not replace live national or local guidance, specialist advice, or current prescribing information.
Full textbook

Galactocele

Recognise a milk-retention cyst during or after lactation, distinguish it from abscess and solid tumour on imaging, and use aspiration or biopsy when symptoms, infection or discordance require intervention.

Saved on this device
Open the sections you need. The overview is shown first.
01OverviewDefinition, clinical context and the essential points that orientate the chapter.

Milk accumulates when a lactating duct becomes obstructed, forming a cyst whose contents separate into variable fat and fluid components. A galactocele may arise while actively feeding or become more apparent after weaning as milk stagnates. It can be soft or firm depending on tension and viscosity, and imaging may show a simple cyst, a fat-fluid level or complex internal echoes.

The diagnostic task is to prove that the milk-containing structure explains the palpable target. Typical imaging and milky aspirate support the diagnosis, but a persistent mural nodule, vascular solid component or residual hard mass requires core biopsy. Observe a comfortable concordant lesion; diagnostic aspiration remains useful when contents are uncertain. For a large symptomatic galactocele, ABM Protocol 36 recommends drain placement: viscous milk often drains incompletely or refills after aspiration, and repeated aspirations can introduce infection. An infected collection needs drainage plus antibiotics. Feeding support addresses obstruction without unnecessary cessation.

Key points

  • A galactocele is a milk-retention cyst caused by duct obstruction during pregnancy, breastfeeding or soon after weaning and commonly presents as a painless mobile mass.
  • Ultrasound appearances vary with fat, protein and water content; a fat-fluid level is suggestive, while thick contents can create internal echoes that resemble a solid lesion.
  • Clinical and imaging assessment must localise the same mass because lactation does not protect against fibroadenoma, abscess or pregnancy-associated breast cancer.
  • A small asymptomatic concordant galactocele can be observed while feeding continues; many resolve as lactation and duct obstruction settle.
  • For a symptomatic galactocele, ABM36 recommends a drain to relieve pressure and improve attachment because aspiration often leaves or reaccumulates milk, and repeated aspirations increase infection risk. Diagnostic aspiration and drainage of a simple breast abscess are separate decisions.
  • Pain, erythema, fever, purulent aspirate or surrounding hyperaemia suggests secondary infection requiring culture, antibiotics and source control rather than simple reassurance.
02AetiologyUnderlying causes, associations and risk factors, with why each one matters.
01

Duct obstruction

Local compression, inflammation, abrupt feed change or thick milk impedes outflow from a lactating lobule and creates retention.

02

Post-weaning stasis

Milk production may continue briefly after feeding decreases, allowing secretion to accumulate behind a duct that is no longer emptied regularly.

03PathophysiologyThe causal sequence from the underlying abnormality to symptoms and harm.
  1. 1
    Milk accumulation

    Retained milk progressively distends a duct-lobular space and forms a palpable cyst lined by flattened epithelium.

  2. 2
    Fat-fluid separation

    Milk lipids rise above the aqueous component, creating a diagnostic fat-fluid interface on mammography or ultrasound.

  3. 3
    Secondary infection

    Stagnant nutrient-rich contents can become infected through duct or skin routes, converting a sterile cyst into an abscess.

04Clinical features and red flagsSymptoms, examination findings, patterns of presentation and time-critical warnings.
Lactational timing

A new mass during established milk production or soon after abrupt weaning supports retained milk, especially when fullness varies with feeding or expression.

Usually non-inflammatory

An uncomplicated galactocele is often painless, mobile and without fever or erythema. Marked tenderness or systemic illness suggests secondary infection or another diagnosis.

Variable consistency

High fat content may feel soft while protein-rich thick milk and rising pressure make the lump firm, so palpation alone cannot separate it from solid tissue.

Atypical residual feature

Fixation, skin change, abnormal nodes or a solid vascular component is not explained by a simple retention cyst and must enter the breast diagnostic pathway.

05InvestigationsWhat to request, why it matters and how to interpret it.
Investigation order

Read from the initial assessment onwards. Tests may run in parallel in urgent care; first-line, preferred, confirmatory, definitive and gold-standard labels appear only when the chapter explicitly states them.

  1. 01
    Targeted ultrasoundFirst step
    Why
    Confirm cystic anatomy, assess internal contents and plan a safe route for diagnostic sampling or therapeutic drainage.
    Interpretation and limitations
    A fat-fluid level or avascular echogenic milk supports galactocele. Doppler flow in a mural component or irregular tissue requires biopsy.
  2. 02
    Diagnostic mammography
    Why
    Evaluate an indeterminate lesion or associated abnormality when clinically appropriate during lactation.
    Interpretation and limitations
    A fat-containing mass may be characteristic, but increased lactational density can obscure tissue; negative imaging does not cancel a concerning clinical target.
  3. 03
    Diagnostic aspiration and therapeutic drainage
    Why
    Confirm uncertain milk content or obtain infected fluid for culture; use drain placement for a symptomatic galactocele.
    Interpretation and limitations
    Milky contents support the diagnosis when concordant with the imaged target. Viscosity and rapid refilling limit therapeutic aspiration, so ABM36 favours a drain for symptom relief. A remaining solid component still requires representative tissue assessment.
  4. 04
    Core biopsy of residual tissue
    Why
    Diagnose any solid component not accounted for by retained milk.
    Interpretation and limitations
    The needle targets the persistent tissue, not merely cyst fluid. Benign lactational change is accepted only when representative and concordant.
06Differential diagnosisRealistic alternatives and the features that help distinguish them.
01

Lactational abscess

Pain, fever, erythema, hyperaemia and purulent contents indicate infected fluid needing drainage and antimicrobial assessment promptly.

02

Fibroadenoma or lactating adenoma

Hormone-responsive solid lesions may enlarge during pregnancy and lactation and require ultrasound distinction and sometimes core biopsy.

03

Pregnancy-associated carcinoma

A hard persistent mass, skin change, nodes or solid suspicious imaging cannot be attributed to milk retention without representative tissue.

07ManagementImmediate care, first-line treatment, alternatives and escalation.
01Concordant observation pathwayManage a comfortable milk-retention cystFirst stepA breastfeeding patient has a 2 cm mobile lump; ultrasound shows a classic fat-fluid cyst with no vascular solid component.
  1. 1Map the mass and assess feeding, weaning changes, pain, fever, skin and nodes so the imaging is correlated with the actual target.
  2. 2Explain the milk-retention mechanism and offer observation because the lesion is small, comfortable and radiologically concordant.
  3. 3Arrange feeding support for oversupply or obstruction without instructing aggressive complete emptying that increases production.
  4. 4Give return advice for enlargement, pain, erythema, fever or a persistent mass after lactation and assign review if it does not regress.
02Symptomatic drainage pathwayRelieve pressure and confirm contentsA tense 6 cm galactocele causes pain and interferes with infant positioning at the breast.
  1. 1Use ultrasound to confirm a safe fluid target and exclude a vascular mural nodule before intervention.
  2. 2Discuss drain placement for this painful large galactocele, prepare aseptically and establish effective local infiltration anaesthesia with the checked dose and precautions. Insert an image-guided drain to gravity, document the milk obtained and confirm decompression and improved comfort.
  3. 3Explain that viscous retained milk often empties incompletely or refills after aspiration, and repeated punctures can infect a sterile galactocele. The drain allows continued emptying; agree review of output, symptoms and the residual cavity with the breast team.
  4. 4Review feeding mechanics and symptoms and re-image rapidly recurrent or incompletely collapsing lesions.
03Infected galactocele pathwayTreat an infected milk collectionA galactocele becomes hot and tender with fever and turbid fluid. After urgent assessment, the breastfeeding adult is stable without sepsis, spreading cellulitis or threatened skin; renal function is preserved, the infant is healthy and term, and there is no beta-lactam allergy or MRSA risk.
  1. 1Assess systemic severity and ultrasound the collection for loculation and skin compromise.
  2. 2After local anaesthesia and aseptic preparation, place a drain and send infected milk for culture. Treat this abscess phenotype with the NHS Highland stable-adult example, flucloxacillin 500 mg orally four times daily for 7–10 days, using the card precautions and revising from culture or response. Systemic deterioration requires hospital reassessment.
  3. 3Continue safe milk removal with lactation support while preventing infant contact with purulent wound drainage.
  4. 4Verify clinical and ultrasound resolution and biopsy any persistent solid component after acute inflammation settles.
Key medicines and prescribing safety2 treatments · regimens, roles and cautions
Treats susceptible bacterial infection within retained milk while a drain achieves source control; antibiotics do not replace drainage.

Flucloxacillin for an infected lactational galactocele

After assessment and drainage, the NHS Highland adult breast-abscess example is flucloxacillin 500 mg orally four times daily for 7–10 days. Apply it to a stable patient without relevant allergy or MRSA risk, then review culture and improvement; this differs from the NHS Dumfries & Galloway 10–14-day mastitis pathway.

Use the 500 mg capsules on an empty stomach, one hour before or two hours after meals, with 250 mL water and no immediate lying down. Exclude beta-lactam or product hypersensitivity and previous flucloxacillin-associated jaundice/liver dysfunction. Review hepatic disease and interactions including methotrexate, warfarin/INR, probenecid and voriconazole. CrCl under 10 mL/min needs prescriber consideration of a reduced dose or extended interval. Concurrent paracetamol in severe renal impairment, sepsis or malnutrition requires acidosis-risk review and monitoring. Monitor the healthy term infant for gastrointestinal symptoms, thrush, rash or feeding difficulty; severe maternal illness or an unwell/premature infant needs individual specialist advice.

Makes the planned diagnostic puncture or drain insertion tolerable after consent, aseptic preparation and confirmation of the fluid target.

Lidocaine 10 mg/mL for drainage-site anaesthesia

Use plain Aguettant 1% lidocaine by local intradermal/subcutaneous infiltration, selecting the minimum effective volume. The product gives a usual adult infiltration total of 3–5 mg/kg and a generally recommended 200 mg ceiling, equivalent to 20 mL. Do not aim for the ceiling; adjust the dose to the patient and procedure.

An experienced clinician with resuscitation facilities should administer it. Amide-local-anaesthetic/product allergy excludes use; cardiac or liver insufficiency may need up to a half-dose reduction, and renal impairment or frailty can require further individual adjustment. Review conduction disease, seizures, anticoagulants, other local anaesthetics and antiarrhythmic/metabolic interactions. Infected tissue has poorer anaesthetic effect and greater systemic absorption; avoid intravascular injection and monitor for toxicity. Stop and initiate urgent assessment/resuscitation for perioral sensory change, tinnitus, seizures, arrhythmia or collapse. The IVRA 3 mg/kg maximum and adrenaline-mixture rules are not infiltration rules; recommended local doses are compatible with continued breastfeeding.

08ComplicationsImportant consequences, why they occur and why they matter clinically.
01

Painful enlargement

A tense large cyst can disturb sleep, arm movement and attachment. A drain can relieve its mass effect while reducing the repeated aspiration and refilling cycle described in ABM36.

02

Infection and abscess

Secondary bacterial infection produces pus, cellulitis and systemic symptoms and requires source control in addition to antibiotics.

03

Recurrence or milk fistula

Persistent obstruction can refill the cavity, while intervention near active ducts rarely produces prolonged milk drainage through skin.

09Monitoring and follow-upTreatment response, safety checks and longer-term review.
  • Record cyst dimensions, symptoms and relationship to feeding or weaning so interval change is interpreted against lactational physiology.
  • After diagnostic aspiration or therapeutic drain placement, document the residual cavity and check decompression, drainage, bruising, leakage and infection. Rapid refill or a blocked drain needs prompt breast-team review rather than an automatic sequence of repeat aspirations.
  • For infected lesions, review fever, erythema, culture, antimicrobial response and residual cavity within a defined short interval.
  • Reassess a mass that persists after weaning or loses its typical fat-fluid features rather than extending the galactocele label indefinitely.
10Special situationsVariants, exceptions and circumstances that change the usual approach.

Milk composition alters imaging

Fat separates from aqueous milk and protein can become thick, explaining why one galactocele appears simple while another looks echogenic or complex.

Aspiration can be difficult

Thick milk may yield poorly through a needle, so a scant diagnostic aspirate does not establish solid tumour. Recheck imaging; for symptomatic retained milk, use the drain strategy to address incomplete emptying and refilling while investigating any genuine solid target.

Cancer can coexist with lactation

Pregnancy and breastfeeding raise the likelihood of benign milk lesions but cannot explain fixation, nodes or an imaging solid component without tissue diagnosis.

Feeding need not stop

A sterile galactocele is not infectious and indicated diagnostic sampling or drainage does not routinely require weaning. Maintain comfortable feeding, support attachment and keep the infant clear of purulent drainage if infection develops.

11Common pitfallsFrequent interpretation and management errors.
  1. 01

    Calling every lactational lump a blocked duct can delay imaging of an abscess or pregnancy-associated breast cancer.

  2. 02

    Assuming internal echoes are always thick milk can miss a vascular papillary or other solid component.

  3. 03

    Aspirating a symptomatic cyst without confirming collapse leaves uncertainty about whether it explained the palpable mass.

  4. 04

    Telling the patient to pump repeatedly to complete emptiness can drive oversupply and recurrent milk retention.

Practice

Two practice questions

Question 1 of 20 correct
Breast surgeryOriginal SBA

Typical small galactocele

A breastfeeding patient has a painless mobile 2 cm lump and ultrasound shows a classic fat-fluid cyst without a vascular solid component. The findings explain the palpable target. What is appropriate?

Sources and review status8 sources · checked 7 Sept 2026 · clinical review pending
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 7 Sept 2026; clinical approval remains outstanding.

Authoring stateComplete draftClinical stateAwaiting reviewJurisdictionUnited Kingdom